Literature DB >> 6318787

Ranitidine disposition in patients with renal impairment.

P J Meffin, N Grgurinovich, P M Brooks, J O Miners, M Cochran, G Stranks.   

Abstract

Ranitidine disposition has been studied in 12 patients with renal impairment following 50 mg given intravenously and 150 mg given by mouth on separate occasions. The clearance of ranitidine from plasma (y) was correlated with creatinine clearance (x): y = 10.47 + 0.289x,r2 = 0.751, but there was no significant correlation of creatinine clearance with distribution volume or bioavailability. The mean (s.e. mean) distribution volume was 1.62 (0.08) 1/kg and the mean bioavailability 0.81 (0.05). These data suggest that in order to obtain similar ranitidine plasma concentrations in anephric patients and patients with normal renal function, the maintenance dose in the anephric patients should be 25-30% of that for patients with normal renal function.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6318787      PMCID: PMC1428369          DOI: 10.1111/j.1365-2125.1983.tb02252.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  A method for the determination of ranitidine and its metabolites in urine by h.p.l.c. and its application to study the metabolism and pharmacokinetics of ranitidine in man.

Authors:  P F Carey; L E Martin; P Owen
Journal:  Biochem Soc Trans       Date:  1981-02       Impact factor: 5.407

2.  High-pressure liquid chromatographic determination of ranitidine, a new H2-receptor antagonist, in plasma and urine.

Authors:  G W Mihaly; O H Drummer; A Marshall; R A Smallwood; W J Louis
Journal:  J Pharm Sci       Date:  1980-10       Impact factor: 3.534

3.  Evaluation of a new multichannel analyzer, "Astra-8".

Authors:  P R Finley; R J Williams; D A Lichti; A C Thies
Journal:  Clin Chem       Date:  1978-12       Impact factor: 8.327

4.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

5.  Ranitidine: single dose pharmacokinetics and absolute bioavailability in man.

Authors:  A M van Hecken; T B Tjandramaga; A Mullie; R Verbesselt; P J de Schepper
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

Review 6.  Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

7.  Pharmacokinetics of the H2- receptor antagonist ranitidine in man.

Authors:  J J McNeil; G W Mihaly; A Anderson; A W Marshall; R A Smallwood; W J Louis
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

  7 in total
  10 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part I).

Authors:  J P Fillastre; E Singlas
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

2.  A pharmacokinetic study of roxatidine acetate in chronic renal failure.

Authors:  N Lameire; B Rosenkranz; L Maass; D Brockmeier
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

4.  Does H2 receptor antagonist-resistant ulcer exist?--A review based on bioavailability in man.

Authors:  K Kawai
Journal:  Gastroenterol Jpn       Date:  1992-06

5.  The effect of renal function on the pharmacokinetics of ranitidine.

Authors:  J S Dixon; J M Borg-Costanzi; S J Langley; L F Lacey; S Toon
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 6.  Renal effects of peptic ulcer therapy.

Authors:  E Burgess; D Muruve
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

7.  Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis.

Authors:  D A Sica; T Comstock; A Harford; F Eshelman
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 8.  Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency.

Authors:  U Gladziwa; U Klotz
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 9.  Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure.

Authors:  U Gladziwa; U Koltz
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

10.  Pharmacokinetics of ranitidine in critically ill patients.

Authors:  K F Ilett; R L Nation; R Tjokrosetio; W R Thompson; T E Oh; P D Cameron
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.